We are live on ! Find out more
AI

Allostery Investments Portfolio holdings

AUM $7.85M
This Fund
S&P 500
This Quarter Est. Return
+35.03%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$7.85M
AUM Growth
-$61.5M
Cap. Flow
-$62.1M
Cap. Flow %
-791.46%
Top 10 Hldgs %
82.66%
Holding
46
New
5
Increased
1
Reduced
14
Closed
26

Top Buys

Rank Stock Value
1
RZLT icon
Rezolute
RZLT
+$443K
2
FULC icon
Fulcrum Therapeutics
FULC
+$216K
3
AKRO
Akero Therapeutics
AKRO
+$204K
4
TRML
Tourmaline Bio
TRML
+$152K
5
TNGX icon
Tango Therapeutics
TNGX
+$98.9K

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$6.08M
2
MRUS
Merus
MRUS
+$5.44M
3
KALV
KalVista Pharmaceuticals
KALV
+$5.11M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$4.18M
5
APGE icon
Apogee Therapeutics
APGE
+$3.96M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$11B
$1.28M 16.31%
167,350
-932,304
-85% -$6.08M
AKRO
2
DELISTED
Akero Therapeutics
AKRO
$1.2M 15.29%
22,500
+4,500
+25% +$204K
AMLX icon
3
Amylyx Pharmaceuticals
AMLX
$2.05B
$770K 9.81%
120,119
-145,980
-55% -$710K
CNTA
4
DELISTED
Centessa Pharmaceuticals
CNTA
$690K 8.79%
52,500
-330,024
-86% -$4.18M
EOLS icon
5
Evolus
EOLS
$394M
$553K 7.04%
60,000
-352,754
-85% -$3.61M
RZLT icon
6
Rezolute
RZLT
$480M
$532K 6.78%
+119,294
New +$443K
MRUS
7
DELISTED
Merus
MRUS
$473K 6.03%
9,000
-115,657
-93% -$5.44M
KALV
8
DELISTED
KalVista Pharmaceuticals
KALV
$452K 5.76%
40,000
-418,302
-91% -$5.11M
FULC icon
9
Fulcrum Therapeutics
FULC
$248M
$278K 3.54%
+40,353
New +$216K
APGE icon
10
Apogee Therapeutics
APGE
$10.2B
$261K 3.32%
6,000
-104,000
-95% -$3.96M
VRNA
11
DELISTED
Verona Pharma
VRNA
$236K 3.01%
2,500
-10,000
-80% -$740K
TNGX icon
12
Tango Therapeutics
TNGX
$4.34B
$205K 2.61%
+40,000
New +$98.9K
BBIO icon
13
BridgeBio Pharma
BBIO
$16.5B
$173K 2.2%
4,000
-76,000
-95% -$2.76M
CYTK icon
14
Cytokinetics
CYTK
$11B
$165K 2.1%
5,000
-65,000
-93% -$2.26M
TRML
15
DELISTED
Tourmaline Bio
TRML
$150K 1.91%
+9,356
New +$152K
LEGN icon
16
Legend Biotech
LEGN
$4.3B
$142K 1.81%
4,000
-750
-16% -$24.3K
NKTR icon
17
Nektar Therapeutics
NKTR
$2.39B
$103K 1.32%
+4,000
New +$44.9K
PMN icon
18
ProMIS Neurosciences
PMN
$109M
$76.3K 0.97%
6,229
-3,119
-33% -$42.6K
ACLX
19
DELISTED
Arcellx
ACLX
$65.8K 0.84%
1,000
-43,000
-98% -$2.68M
AVTX icon
20
Avalo Therapeutics
AVTX
$976M
$44.9K 0.57%
9,000
-98,141
-92% -$458K
ALKS icon
21
Alkermes
ALKS
$8.82B
– –
-115,000
Closed -$3.8M
ARQT icon
22
Arcutis Biotherapeutics
ARQT
$3.42B
– –
-7,500
Closed -$117K
JBIO
23
Jade Biosciences
JBIO
$1.22B
– –
-40,616
Closed -$3.57M
BEAM icon
24
Beam Therapeutics
BEAM
$2.58B
– –
-92,754
Closed -$1.81M
CNTX icon
25
Context Therapeutics
CNTX
$56.4M
– –
-950,166
Closed -$582K
1
2

Similar funds

CP
Castalian Partners Excelsior, Minnesota $7.36M AUM
CAWM
Capital A Wealth Management New Castle, Pennsylvania $8.94M AUM
ADIM
Alpha DNA Investment Management Columbia, Maryland $8.98M AUM 26.05% 1-Year Est. Return
PC
Prysm Capital Princeton, New Jersey $10.6M AUM 2.38% 1-Year Est. Return
AVM
Altos Ventures Management Burlingame, California $11.7M AUM 182.72% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
BPWM
Black Point Wealth Management Naples, Florida $3.5M AUM 16.42% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return

Allostery Investments's Q2 2025 Portfolio in Review

As of Q2 2025, Allostery Investments held 46 positions worth $7.85M, down 89% from $69.3M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Allostery Investments withdrew a net $62.1M in Q2 2025, closing 26 positions and reducing 14 holdings. Its most notable exit was Alkermes, an estimated $3.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Allostery Investments opened a new position in Rezolute worth $532K.

  • Allostery Investments's largest Q2 2025 buy was Rezolute: 119,294 shares worth $532K.
  • Allostery Investments added most to Akero Therapeutics in Q2 2025, an estimated $204K increase.
  • Allostery Investments's biggest Q2 2025 reduction was Abivax, cutting an estimated $6.08M.
  • Allostery Investments fully exited Alkermes in Q2 2025, selling an estimated $3.8M.
  • Allostery Investments's ten largest holdings make up 83% of its $7.85M portfolio in Q2 2025.
  • Allostery Investments opened 5 new positions and closed 26 in Q2 2025.
  • Allostery Investments's portfolio value fell 89% quarter-over-quarter to $7.85M.

Based on Allostery Investments's 13F filing for Q2 2025, filed 14 Aug 2025.